Background parenchymal enhancement in CEM and MRI: Is there always a high agreement?

Introduction: Background parenchymal enhancement (BPE) refers to the physiological enhancement of breast fibroglandular tissue. This study aimed to determine the agreement of BPE evaluation between contrast enhanced mammography (CEM) and magnetic resonance imaging (MRI) and investigate potential confounders.

Materials And Methods: This retrospective, IRB-approved study included women recalled from screening or with inconclusive findings on mammography and/or ultrasound, who underwent both CEM and MRI between 2018 and 2022.

Added value of body MRI to detect primary abdominal malignancies in the diagnostic work-up of patients with adenocarcinoma of unknown primary.

Purpose: This study aimed to evaluate the added benefit of body MRI (covering the chest, abdomen, and pelvis) to detect the primary tumour in patients with adenocarcinoma of unknown primary (ACUP) and a suspected abdominal malignancy in whom previous diagnostic work-up with CT and/or FDG-PET/CT did not yield a primary tumour diagnosis.

Methods: Thirty ACUP patients with a suspected primary tumour in the abdomen/pelvis (based on pathology and/or pattern of disease) underwent MRI (T2-weighted, DWI, pre- and post-contrast T1-weighted) after completion of their initial diagnostic work-up with CT and/or PET/CT. Effects of MRI to establish a primary tumour diagnosis (and to detect additional metastatic sites) were documented.

Intra-prostatic recurrences after radiotherapy with focal boost: Location and dose mapping in the FLAME trial.

Introduction: The FLAME trial demonstrated that the dose to the gross tumor volume (GTV) is associated with tumour control in prostate cancer patients. This raises the question if dose de-escalation to the remaining prostate gland can be considered. Therefore, we investigated if intraprostatic recurrences occur at the location of the GTV and which dose was delivered at that location.